Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 45 Univ. Hospitals to Consider Joint Purchases
June 29, 2009
- New Dosage, Treatment Regimens Expected to Become Patentable
June 29, 2009
- GENERICS NEWS IN BRIEF
June 29, 2009
- Revised Pricing Rule Had Little Effect on Pricing of New Drugs in FY2008: FPMAJ
June 29, 2009
- Prof. Kudo Calls For Proper Use of Nexavar for HCC
June 29, 2009
- Range of Drugs Eligible for Price Protection Proposed by FPMAJ Is Reasonable: Report
June 29, 2009
- Sorafenib May Be Used in Wide Range of Patients
June 29, 2009
- Sales of Ethical Drugs Up 0.2% in April
June 29, 2009
- Tamiflu Is Not Ineffective against Resistant Viruses
June 29, 2009
- BUSINESS NEWS IN BRIEF
June 29, 2009
- Pandemic of New-Type Flu Infections Unavoidable in Japan in Oct-Nov: Prof. Oshitani
June 29, 2009
- TOPICS 2 articles
June 29, 2009
- Memantine Dosage Titration Necessary in Patients with Renal Disorders
June 29, 2009
- Zithromac Leaps to Top Place in April: Rep Track Survey
June 29, 2009
- Expert Committee Recommends HbA1C for Diagnosis of Diabetes
June 29, 2009
- Distribution Business Reform in FY2008 Was Failure: Mr Matsutani
June 29, 2009
- Larger-Scale, Dose-Finding PII Studies Necessary for Anticoagulants: Dr C.M. Gibson
June 22, 2009
- Give Incentives to Those Who Settle Prices Earlier: Mr Bessho
June 22, 2009
- New Antithrombotic Drugs That Solve Dilemma of Thrombotic Events and Hemorrhagic Events Needed: Prof. Goto
June 22, 2009
- Mediceo Paltac to Invest in Drug Wholesaler in China
June 22, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…